Send to

Choose Destination
See comment in PubMed Commons below
Int J Breast Cancer. 2012;2012:385978. doi: 10.1155/2012/385978. Epub 2012 Jan 24.

Triple-negative breast cancer: an update on neoadjuvant clinical trials.

Author information

Division of Surgical Oncology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.


Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center